ClinicalTrials.gg
RecruitingNCT07938333VitD_PedsOncoUpdated Nov 16, 2026

Impact of Vitamin D on Gut Microbiome and Metabolome Among Pediatric Oncology Patients

An observational study in Acute Lymphoblastic Leukemia ALL, sponsored by Children's Hospital of Orange County. Recruiting at 1 site in United States. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Children's Hospital of Orange County · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
0 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 171 open to participants now, 277 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.

Planned enrollment
123rd of 154
30 · median 110
Started
2026
with 38 others
Observational
155 of 1,545
28 open now
Primary completion
2027-08
later than 149 of 275 live
Registered
1,543rd of 1,545
by date

Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 123rd largest by planned enrollment of the 154 observational ones that give a count, is one of 39 that started in 2026, is one of 155 observational ones, reaches primary completion later than 149 of the 275 other live ones, and was the 1,543rd registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

171 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:

165 more — sign in →

All 171 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 0 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, or all of them as a file.
02

Study summary

Brief Summary The purpose of this observational study is to better understand how vitamin D levels affect the gut microbiome (the bacteria that live in the intestines) in children who are newly diagnosed with acute lymphoblastic leukemia (ALL). Researchers want to learn whether low vitamin D levels are linked to changes in gut bacteria and whether this may affect how children with ALL respond to chemotherapy.

The main questions this study aims to answer are:

  • Are the gut bacteria different in children with ALL who have low vitamin D levels compared to those with normal vitamin D levels at the time of diagnosis?
  • How do vitamin D levels relate to changes in gut bacteria and related body processes before and after induction chemotherapy? Researchers will compare children who have low vitamin D levels with those who have normal vitamin D levels to see if there are differences in their gut bacteria and how those bacteria change during early treatment. The stool samples will be studied in specialized laboratories to better understand how vitamin D and gut bacteria interact.

The results of this study may help doctors understand whether monitoring and managing vitamin D levels could improve care and treatment outcomes for children with ALL.

Participants will:

Have four study visits:

  • Screening: Review and sign consent/assent forms, review of Inclusion/Exclusion Criteria, medical history, and current medications
  • At diagnosis (baseline): Review of medications, laboratory results, Vitamin D level, Fecal Sample Collection
  • Day 29-32 - At the end of induction chemotherapy: Review of medications, laboratory results, Vitamin D level, Fecal Sample Collection and Adverse event assessment
  • Day 90-97 after Induction: Review of medications, laboratory results, Vitamin D level, Fecal Sample Collection and Adverse event assessment
Read the detailed description

Detailed description:

This pilot observational study will evaluate how vitamin D (VitD) levels are related to the gut microbiome in children newly diagnosed with acute lymphoblastic leukemia (ALL), and how these relationships change during early chemotherapy treatment.

Aim 1:

To determine whether vitamin D status affects the gut microbiome at the time of ALL diagnosis. The study hypothesizes that children with vitamin D deficiency will have lower gut microbiome diversity and different microbial and metabolomic profiles compared to children with sufficient vitamin D levels.

A baseline stool sample will be collected within ±4 days of starting induction therapy, prior to significant chemotherapy exposure. Samples will be processed and stored at -80°C and analyzed using metagenomic sequencing and untargeted metabolomics to evaluate microbial composition, diversity, and metabolic pathways. Baseline vitamin D levels (25-hydroxyvitamin D [25(OH)D]) and relevant clinical data will be obtained.

Aim 2:

To determine whether maintaining sufficient vitamin D levels during treatment supports gut microbiome diversity and function. As part of standard clinical care, patients with 25(OH)D levels \<30 ng/mL will receive vitamin D supplementation managed by the oncology team.

Follow-up stool samples will be collected:

  • At the end of induction chemotherapy (Day 29-32)
  • 90-97 Days after Induction Microbiome and metabolomic analyses will be conducted on de-identified samples. Participants will be stratified based on vitamin D levels (\<30 vs ≥30 ng/mL) at the end of induction and/or consolidation to evaluate associations between vitamin D status and microbial diversity and function.

Targeted metabolomic analysis will be performed in patients with persistent vitamin D deficiency despite supplementation to explore whether gut microbiota influence vitamin D metabolism. The study will also assess changes in microbiome diversity over time within individuals using a paired design to reduce variability.

Exploratory Outcomes:

Clinical outcomes will be retrospectively collected from medical records to explore associations between gut microbiome diversity and treatment-related outcomes, including:

  • Febrile neutropenia
  • Positive bacterial or viral testing
  • Severe diarrhea or constipation
  • Measurable residual disease (Day 8 and Day 29)
  • Length of hospital stay
  • ICU admission
  • Weight loss Although this pilot study may not be powered to detect statistically significant clinical outcome differences, findings will inform power calculations for future multicenter studies.

Significance:

This study will provide foundational data on the interaction between vitamin D status and the gut microbiome in pediatric ALL. Results may inform future strategies to monitor and optimize vitamin D levels to preserve gut microbial health and potentially improve treatment outcomes in pediatric oncology patients.

03

Conditions studied

  • Acute Lymphoblastic Leukemia ALL

Keywords

  • acute lymphoblastic leukemia
  • vitamin D
  • microbiome
04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Oncology unit at Children's Hospital of Orange County

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 0-18 years
  • Newly diagnosed with acute lymphoblastic leukemia, including B-cell ALL, T-cell ALL, mixed phenotype actue leukemia (MPAL), and Philadelphia-positive or Philadelphia-like ALL.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with other , congenital gastrointestinal or bowel diseases, or inflammatory bowel diseases.
  • to vitamin D.
  • Pregnant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Gut microbiome diversity

    Bacterial 16S ribosomal RNA gene targeted sequencing will be performed using the Quick-16S™ NGS Library Prep Kit (Zymo Research, Irvine, CA). Bioinformatic analysis includes Absolute Abundance, Composition barplots, Taxonomy Heatmaps, Alpha and Beta Diversity, and LEfSe Analysis.

    Time frame: Through study completion, up to 97 days

Secondary outcomes

  1. Baseline 25[OH]D levels

    Clinical outcomes will be collected retrospectively from patients' electronic medical records, including baseline 25(OH)D levels at the time of cancer diagnosis.

    Time frame: Baseline

  2. MRD levels at the end of induction chemotherapy

    Clinical outcomes will be collected retrospectively from patients' electronic medical records, including MRD levels at the end of induction chemotherapy (EOI, Day 29).

    Time frame: At the end of induction chemotherapy (Day 29)

  3. Number of ICU admissions

    Clinical outcomes will be collected retrospectively from patients' electronic medical records, including the number of ICU admissions, over the study period (up to 97 days).

    Time frame: Through study completion (up to 97 days)

  4. Number of infection events

    Clinical outcomes will be collected retrospectively from patients' electronic medical records, including infection events confirmed by blood culture or PCR assay, over the study period (up to 97 days).

    Time frame: Through study completion, up to 97 days

  5. Length of hospital stay

    Clinical outcomes will be collected retrospectively from patients' electronic medical records, including length of hospital stay, over the study period (up to 97 days).

    Time frame: Through study completion, up to 97 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.

Of 145 non-industry observational studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 143. This study's planned 9 months is below that.

Counting every sponsor, half of 163 studies reached it within 54 months; a quarter within 24 and three quarters within 142.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Nov 16, 2026
StartEst.
Nov 9, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938333
Lead sponsor
Children's Hospital of Orange County
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 9, 2026 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Sun Yang, B.Pharm., Ph.D, R.Ph, BCPPS
Contact
syang@chapman.edu
(714) 516-5418
Kathryn Duvall, MSN, RN, CCRP, CPON
Contact
kduvall@choc.org
(714) 509-8646
Rishikesh Chavan, MD
principal investigator · Children's Hospital of Orange County

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion